Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B

Exclusion Criteria

• •History of Acute infection, gastrointestinal bleeding, etc. occurring within 28 days prior to study enrollment.
• •Advanced liver cirrhosis, Child-Pugh score ≥ 7 or clinical symptoms of liver function decompensation such as ascites and varicose veins
• •Positive test for other viral infections, anti-HAV IgM, anti HCV, anti-HDV, anti -HEV and anti-HIV Any item is positive; liver disease caused by other reasons (such as autoimmune liver disease, alcoholic liver disease, non-alcoholic liver disease, drug-induced liver disease and other liver diseases of unknown cause, etc.).
• •History of or suspicion of hepatocellular carcinoma or alpha fetoprotein (AFP) \> 20 ng/mL at Screening. If AFP \> 20 ng/mL, hepatic imaging must exclude hepatocellular carcinoma.
• •History of having received (in the last 6 months) or currently receiving any other cell therapies
• •History of organ transplantation
• •History of severe allergic reaction (hives or anaphylaxis) to blood products
• •History of any Grade 4 immune-related AE from prior immunotherapy. Any immune-related AE that led to permanent discontinuation that occurred less than 6 months prior to leukapheresis or whole blood collection for production
• •Use of any investigational product (IP) within 28 days of study treatment administration.
• •Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples